Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Combination temozolomide and radiation significantly prolongs survival compared with
radiation alone and has become standard treatment for glioblastoma multiforme (GBM).
Response assessment in GBM is difficult as a result of the frequent occurrence of early
imaging changes indistinguishable from tumor progression, termed pseudoprogression. The
majority of patients remain clinically stable. It is often unclear whether current therapy
should be maintained or second-line therapy initiated. The incidence of pseudoprogression
after concurrent chemoradiation is15%to 30%. A potential mechanism of pseudoprogression is
that radiation-induced vascular changes may lead to focal transient increase in gadolinium
enhancement. Dynamic contrast-enhanced (DCE) MR imaging provides a noninvasive means for
quantifying tumor vascular properties.
Observational Model: Cohort, Time Perspective: Prospective
Permeability Map to Distinguish Progression From Pseudoprogression in High-grade glioma
SeungHong Choi, MD, PhD
Seoul National University Hospital(Radiology)
Korea: Institutional Review Board